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Abstract
As the population ages the number of elderly patients presenting with acute myocardial
infarction (AMI) will continue to increase. There has been no head-to-head trial of
thrombolytic therapy versus primary percutaneous coronary intervention (PCI) in this
patient cohort, but there is evidence that favors primary PCI. Most elderly patients are
candidates for primary PCI, but many have contraindications to thrombolytic therapy.
Hemorrhagic complications are more common in the elderly, and many of these patients
present with conditions in which thrombolytic agents have decreased efficacy, such as
heart failure or prior bypass surgery. PCI can also obviate the need for further risk
stratification in most patients.
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AMI = acute myocardial infarction; GISSI = Gruppo Italiano per lo Studio della Streptokinasi nell’Infarcto Miocardico; GUSTO = Global Utilization
of Streptokinase and t-PA for Occluded Coronary Arteries; PAMI = Primary Angioplasty in Myocardial Infarction; PCI = percutaneous coronary
intervention; PTCA = percutaneous transluminal coronary angioplasty; t-PA = tissue-type plasminogen activator.
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Introduction
Patients older than 70 years remain one of the fastest
growing populations. In the USA alone this group
increased from 21.1 million in 1990 to over 25 million in
1999, and is projected to reach nearly 36 million people
by the year 2020. With this in mind, the number of elderly
patients presenting with an ST-segment elevation AMI will
continue to increase. Despite this, there have been no
head-to-head trials of thrombolytic therapy versus PCI that
are specifically designed for this patient population.
However, there are indications from previous trials that
primary PCI is likely to be the superior therapy.
Elderly patients have a documented increase in bleeding
(including intracranial hemorrhage) with thrombolytic
therapy. In fact, age greater than 65 years has been asso-
ciated with an odds ratio of 2.2 (95% confidence interval
1.4–3.5) for intracranial hemorrhage as compared with
younger patients [1–3]. The percentage of women is
higher than that of men among elderly patients, and
hemorrhagic complications are known to be higher in
women (and even greater if their weight is <70kg). Also,
any previous hemorrhagic stroke, which is more common
in elderly patients, is a very strong contraindication to
thrombolytic therapy [4].http://cvm.controlled-trials.com/content/1/3/146
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Elderly patients are likely to have more contraindications to
thrombolytic therapy, more comorbid conditions, and more
adverse hemodynamic and angiographic predictors of
poor outcome than younger patients. A recent pooled
analysis of 3032 patients enroled in primary PCI trials [5]
revealed that patients older than 75 years were more likely
to have a history of hypertension, diabetes mellitus, con-
gestive heart failure, previous coronary revascularization
(PCI or bypass surgery), peripheral vascular disease,
stroke, or chronic obstructive lung disease. At angiogra-
phy they had lower left ventricular ejection fraction, higher
left ventricular end-diastolic pressure, and more two-
vessel or three-vessel coronary disease. In addition, these
patients were significantly more likely to present with an
infarction of Killip class II or higher.
Studies including elderly acute myocardial
infarction patients
Many of the early trials of thrombolytic therapy intentionally
excluded patients aged 75 years or older because of a
perceived increase in bleeding and overall mortality
[6–12]. Later trials began to include these patients, and
especially those that compared thrombolytic therapy with
primary PCI, but the average age in many of these trials
remained approximately 60 years. In the Global Utilization
of Streptokinase and t-PA for Occluded Coronary Arteries
(GUSTO) 1 trial of four regimens of thrombolytic therapy
[13], the overall mortality rate was 7.0%. However, the
30-day mortality rates for patients aged 65–74, 74–85
and >85 years were 9.5, 19.6 and 30.3%, respectively
[14]. In an analysis of the GUSTO IIb trial, Holmes et al
[15] showed that, for each 10-year patient group (50–59
years, 60–69 years, etc), outcome was always superior
with angioplasty as compared with tissue-type plasmino-
gen activator (t-PA). In the Primary Angioplasty in Myocar-
dial Infarction (PAMI)-1 trial [16], the benefit of
percutaneous transluminal coronary angioplasty (PTCA)
over t-PA was marked in patients aged more than 65
years, with a reduction in the 6-month composite end-
point of in-hospital death or reinfarction being reduced
from 20 to 8.6% (P<0.05).
Recently, Thiemann et al [17] reported an analysis of 7864
patients (aged 65–86 years) who were eligible for throm-
bolytic therapy (presentation <12h from symptom onset,
ST-segment elevation ³1.5mm [limb leads] or ³2mm [pre-
cordial leads] in two or more contiguous leads; left bundle
branch block was excluded). That study was designed to
compare the risks and benefits of intravenous thrombolysis
in patients aged 65–75 years with those in patients aged
76–86 years. Of note, over 50% of the patients in each
group who met initial electrocardiographic criteria were
excluded for various reasons, with 12% of the younger
patients and 17% of the older patients having absolute
contraindications to thrombolytic therapy. Intravenous
thrombolysis was administered in 3861 out of 5191 (74%)
of patients in the 65–75 years age group and in 1607 out
of 2673 (60%) of the 76–86 years age group. At 30 days
there was a survival benefit in the younger patients (hazard
ratio 0.76, 95% confidence interval 0.61–0.95) and wors-
ened survival in the older group (hazard ratio 1.29, 95%
confidence interval 1.06–1.58), with mortality rates
reduced from 9.8 to 6.8% in the younger group but
increased from 15.4 to 18% in the older group (Fig. 1). On
further analysis, death began to increase with thrombolysis
after age 74.3 years. Thiemann et al speculated that
increased rates of intracranial hemorrhage and cardiac
rupture in the older patients may explain the lack of benefit
of thrombolytic therapy in these persons.
Selected patient subsets
With regard to prior coronary bypass surgery, several
studies have shown that thrombotic occlusion of a saphe-
nous vein graft is the primary mechanism of AMI in these
patients. Thrombolytic therapy is often ineffective because
of poor flow in the graft (preventing delivery of the throm-
bolytic agent) as well as the presence of giant thrombus.
Primary PCI is successful in up to 90% of these patients
because the obstructing thrombus can be mechanically
disrupted [18,19].
As mentioned above, older patients are more likely to
present with congestive heart failure. Systemic throm-
bolytic therapy has not been shown to provide a survival
benefit in these patients. In the Gruppo Italiano per lo
Studio della Streptokinasi nell’Infarcto Miocardico
(GISSI)-1 [20] and International Study Group (ISG) [21]
trials, 17–23% of patients presented in Killip class II and
2–4% in class III. At 6-month follow-up in the GISSI-1 trial,
mortality rates were 27% versus 29% for placebo in
class II patients, and 50% versus 53% for placebo in
class III patients (class IV patients were excluded). Like-
wise, no survival benefit for either group was seen in the
ISG trial. It is theorized that poor cardiac pump function
Figure 1
Effect of treatment with thrombolytic therapy for ST-segment elevation
AMI by age group. HR, hazard ratio. Data from Thiemann et al [17].Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 DeGeare and Grines
results in decreased coronary perfusion, making the throm-
bolytic agents unable to penetrate the occlusive thrombus.
Advantages of primary percutaneous coronary
intervention
In a pooled analysis of the PAMI-1, Zwolle and Mayo
Clinic trials, O’Neill et al [22] showed an increasing
benefit of primary PTCA over t-PA with increasing patient
age (Fig. 2). This is probably due to the fact that primary
PCI can restore Thrombolysis in Myocardial Infarction
(TIMI) grade 3 flow in over 90% of patients, as opposed to
60–70% of patients treated with thrombolytic therapy.
Data from primary PCI trials [5] revealed a mortality rate of
approximately 10% in patients older than 75 years, which
is lower than that in the thrombolytic trials.
Emergent catheterization not only defines the status of the
infarct-related artery (patent or not, TIMI flow grade), but is
extremely useful for risk stratification. Significant left main
and multivessel disease can be delineated and hemody-
namics can be assessed. An intra-aortic balloon pump can
be inserted immediately if required. Noninvasive testing
can usually be averted and hospital discharge can be
accelerated, resulting in significant cost savings.
As a result of perceived or real contraindications, fewer
than 10% of elderly patients with ST-segment elevation
AMI receive thrombolytic therapy [23]. Primary PCI is not
as readily available as thrombolytic therapy in all locations,
but there are emerging data [24] that show that primary
PCI can be performed safely in hospitals without on-site
cardiac surgery. This may allow many more patients
access to immediate catheter-based reperfusion.
Future insights
Of course, what is most needed is a head-to-head,
prospective study of thrombolytic therapy versus primary
PCI in elderly patients. The Senior PAMI trial will enrol 530
elderly AMI patients, who will be randomized to primary
PCI or thrombolytic therapy (t-PA or rPA) with a primary
composite end-point of death or disabling stroke at
30 days. Multiple secondary end-points will be measured
at 1, 6, and 12 months.
There may also be a role for combination therapy, in which
reduced-dose thrombolytic therapy (with or without a gly-
coprotein IIb/IIIa receptor antagonist) is administered in
the field or in the receiving emergency room, with subse-
quent transfer for PCI (‘facilitated angioplasty’) [25].
Conclusion
As the population increases worldwide, the number of
elderly patients who present with an ST-segment elevation
AMI will continue to grow. There are no head-to-head trials
of primary PCI versus thrombolytic therapy in elderly
patients. However, data from previous trials that have
included elderly patients suggest that primary PCI is safer
and is probably more effective in such cohorts. The bleed-
ing risk associated with PCI is lower, and PCI appears to
be more effective in patients with prior coronary artery
bypass grafting and those with congestive heart failure,
groups that are more common among elderly patients.
Primary PCI allows those patients who are not eligible for
thrombolytic therapy to receive reperfusion therapy, is
useful for early risk stratification, and usually obviates the
need for noninvasive testing. Early discharge, with resul-
tant lower hospital charges, is also possible in many
cases. Access to primary PCI is expanding, and continued
technical and therapeutic advances will allow for
increased distribution and utilization of this therapy among
elderly patients. The ongoing Senior PAMI trial will provide
the first randomized, controlled trial evidence of throm-
bolytic therapy versus PCI in elderly patients.
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